OpenScience.ink

4 days ago • Frontiers in nutrition

Changes in eating experience during GLP-1 receptor agonist treatment explained by food enjoyment and desireAltered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour.

📖 Top 20% JournalArticle

5 days ago • Diabetology & metabolic syndrome

Possible benefits of GLP-1 receptor activators and SGLT2 blockers for nerve damage in diabetesTherapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.

📖 Top 20% JournalArticle

6 days ago • Journal of general internal medicine

Costs and Affordability of Diabetes Drugs Like GLP-1 Agonists in the US from 2013 to 2023Spending and Affordability of Glucagon-Like Peptide-1 Receptor Agonists and Other Incretin Mimetics in the United States, 2013-2023.

🥉 Top 5% JournalArticle

1 week ago • Journal of clinical medicine

Mouth Health Effects of GLP-1 Receptor Agonists and Similar Diabetes TreatmentsOral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.

📖 Top 20% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

New potential medicines for obesity beyond current hormone-based treatmentsA Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy.

📖 Top 20% JournalArticle

1 week ago • Nutrients

Plant-Based Compounds as Additional Treatments for Obesity Beyond GLP-1 DrugsBeyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.

🎖️ Top 10% JournalArticle

1 week ago • Frontiers in endocrinology

Gut bacteria may influence how people respond to GLP-1 receptor drugsThe gut microbiota as a potential determinant of response to GLP-1 receptor agonists: a narrative review.

🎖️ Top 10% JournalArticle

1 week ago • Nutrients

Understanding Obesity as a Disease Affecting Multiple Body Systems: Improving Research, Diagnosis, and TreatmentUnderstanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.

🎖️ Top 10% JournalArticle

1 week ago • Pharmaceutics

Making Oral Tirzepatide Tablets Using Sodium Caprate to Improve Peptide Absorption in the StomachOvercoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.

📖 Top 20% JournalArticle

1 week ago • European heart journal open

Glucagon-like peptide-1 receptor agonists linked to heart, cancer, and survival benefits in diabetic patients treated with anthracyclinesGlucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.

🎖️ Top 10% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

How Peptide Hormones Work Together to Control AppetitePeptide Hormones in Appetite Regulation: A Complex Network.

📖 Top 20% JournalArticle

1 week ago • Biomedicines

Unexpected Uses of Semaglutide and Tirzepatide in Cancer and Human ReproductionUnconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction.

📖 Top 20% JournalArticle

1 week ago • Frontiers in medicine

Using body traits and genetics to guide personalized drug treatment for obesityPhenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

How Psyllium and Glucomannan Fibers Influence Gut Bacteria, Hormones, Inflammation, and Treatment for MetabolismPsyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.

📖 Top 20% JournalArticle

1 week ago • British journal of clinical pharmacology

Changes in public and private use of diabetes medicines called GLP-1 in Australia from 2020 to 2025Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

📖 Top 20% JournalArticle

1 week ago • Biomedicines

Tirzepatide reduces artery changes after injury in mice with and without diabetes, compared to semaglutideTirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

How Incretin-Based Drugs May Boost Sports Performance and Their Implications for DopingIncretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.

📖 Top 20% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

Exenatide may reduce sudden liver damage from Doxorubicin by affecting cell stress and repair signalsExenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Different Patient Responses Over 12 Months in Type 2 Diabetes Linked to ObesityPatient-Level Multidimensional Response Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Kidney and blood sugar changes after starting Semaglutide in adults with type 2 diabetes and mild kidney diseaseReal-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease.

📖 Top 20% JournalArticle

1 week ago • Cells

Effects of Liraglutide and Exercise on Stress Hormone Gland Changes in Rats During Menopause TransitionChanges in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.

🎖️ Top 10% JournalArticle

1 week ago • Cells

Orforglipron, a Small Drug Activating GLP-1 Receptors, May Protect the Brain and Reduce InflammationOrforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.

🎖️ Top 10% JournalArticle

1 week ago • Journal of cardiovascular development and disease

Heart failure with normal pumping linked to heart and metabolism problems: patterns, causes, and lifestyle changesCardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.

📖 Top 30% JournalArticle

1 week ago • Journal of cardiovascular development and disease

GLP-1 Receptor Drugs as Possible Heart Protectors During Cardiac SurgeryGLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.

📖 Top 30% JournalArticle

1 week ago • Cells

Incretin-Based Treatments, Obesity-Related Inflammation, and Risk of Artery DiseaseIncretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk.

🎖️ Top 10% JournalArticle

1 week ago • Frontiers in microbiology

How Tirzepatide May Affect Gut Bacteria and Metabolism in Obesity TreatmentTirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.

📖 Top 20% Journal

1 week ago • Frontiers in endocrinology

Monoclonal antibody treatments for diabetic kidney disease: from how they work to clinical resultsTherapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence.

🎖️ Top 10% Journal

1 week ago • Frontiers in endocrinology

Comparing effects of GLP-1 receptor drugs, metformin, and inositol on body measurements and metabolism in women with polycystic ovary syndromeComparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.

🎖️ Top 10% Journal

1 week ago • Frontiers in endocrinology

How Albiglutide Affects Heart Muscle Contraction in Humans and MiceContractile effects of albiglutide in the human and mouse atrium.

🎖️ Top 10% Journal

2 weeks ago • Frontiers in endocrinology

Effectiveness and safety of oral GLP-1 medicines for type 2 diabetes and obesityInvestigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.

🎖️ Top 10% Journal

← prevpage 2 of 14next →

GLP-1 Therapies Research Papers